Journal of aerosol medicine and pulmonary drug delivery · 2026
Usability of Levodopa Cyclops® Compared to INBRIJA® During an off Episode in Parkinson's Disease Patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wangsawirana Valesca, de Jong Lara, Meulen Annebet van der, Hagedoorn Paul, Luinstra Marianne, Frijlink Henderik Willem
Аннотация
BACKGROUND: This study compares the usability of two levodopa dry powder inhalers. The Inbrija® inhaler involves several preparatory steps, including blister opening and capsule insertion. The Cyclops® inhaler is preloaded and disposable, designed for immediate use. Ease of use is critical, as cognitive and motor impairments may hinder the patients' ability to operate an inhaler.
METHODS: Sixteen patients with Parkinson's disease experiencing predictable and recognizable off episodes were enrolled. After receiving inhalation instructions, patients performed the inhalation maneuver during their off-episode to assess the correct execution. They completed a questionnaire evaluating the ease of use for both devices. Each patient used both the Cyclops® and Inbrija® inhalers in a randomized sequence and completed the questionnaire.
RESULTS: All 16 patients correctly performed the Cyclops® inhaler steps during an off episode, while only 10 patients successfully completed the steps with the Inbrija® inhaler. Twelve of the sixteen patients (75%) expressed a preference for the Cyclops®, rating it higher in terms of ease of use and hygiene. However, concerns were raised regarding the environmental sustainability of its single-use design. For the Inbrija®, patients reported difficulties with opening the peel-off blister packaging, assembling the mouthpiece, and puncturing the capsules.
CONCLUSION: The Cyclops® inhaler was more user-friendly during off episodes due to its ease of use and simpler handling. Since the Cyclops® is preloaded, it requires fewer and simpler steps. The preparation steps of Inbrija® posed usability challenges, particularly with opening the peel-off blister packaging of the capsule and assembling the mouthpiece and handle.
METHODS: Sixteen patients with Parkinson's disease experiencing predictable and recognizable off episodes were enrolled. After receiving inhalation instructions, patients performed the inhalation maneuver during their off-episode to assess the correct execution. They completed a questionnaire evaluating the ease of use for both devices. Each patient used both the Cyclops® and Inbrija® inhalers in a randomized sequence and completed the questionnaire.
RESULTS: All 16 patients correctly performed the Cyclops® inhaler steps during an off episode, while only 10 patients successfully completed the steps with the Inbrija® inhaler. Twelve of the sixteen patients (75%) expressed a preference for the Cyclops®, rating it higher in terms of ease of use and hygiene. However, concerns were raised regarding the environmental sustainability of its single-use design. For the Inbrija®, patients reported difficulties with opening the peel-off blister packaging, assembling the mouthpiece, and puncturing the capsules.
CONCLUSION: The Cyclops® inhaler was more user-friendly during off episodes due to its ease of use and simpler handling. Since the Cyclops® is preloaded, it requires fewer and simpler steps. The preparation steps of Inbrija® posed usability challenges, particularly with opening the peel-off blister packaging of the capsule and assembling the mouthpiece and handle.